RecruitingNCT06548152

AQUALIS:QoL of CLL Patients Treated With Acalabrutinib in France, Retrospective Study Based on Data From PLATON Database

AQUALIS: Quality of Life of Patients With Chronic Lymphocytic Leukemia Treated With Acalabrutinib in France: a Retrospective Observational Study Based on Data Extracted From the PLATON Database

Sponsor

AstraZeneca

Enrollment

120 participants

Start Date

Apr 28, 2025

Study Type

OBSERVATIONAL

Conditions

Chronic Lymphocytic Leukemia

Summary

QoL is often not assessed in real-world studies; hence, there is limited understanding about the real-world QoL of patients diagnosed with CLL. Besides, studies evaluating QoL have largely focused on comparing treated and untreated populations. In particular, QoL of patients treated with acalabrutinib has not been evaluated in a real-life setting. The aim of this study is to describe the QoL of CLL patients treated with acalabrutinib between the treatment initiation and twelve months after, in a real-life setting.

Eligibility

Plain Language Summary

Simplified for easier understanding

This is a real-world study (not a treatment trial) looking at the quality of life of patients in France with chronic lymphocytic leukemia (CLL) — a type of blood cancer — who are being treated with a drug called acalabrutinib for the first time. The study uses data already collected in the PLATON health database in France to understand how patients feel and function during treatment. **You may be eligible if...** - You are 18 years of age or older - You are already enrolled in the PLATON patient database in France - You have CLL and are being treated with acalabrutinib (alone or combined with obinutuzumab) as your first-ever CLL treatment - You agree to allow your health data to be used for this research **You may NOT be eligible if...** - You are pregnant - You have previously received treatment for CLL before acalabrutinib - You are under legal protection that prevents consent - You are unable to express your agreement to participate Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(1)

Research Site

Saint-Affrique, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06548152

Related Trials

A Long-term Extension Study of PCI-32765 (Ibrutinib)

NCT01804686175 locations

Economic Analysis of Early vs Delayed Therapy in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma:

NCT053718088 locations

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

NCT0509142431 locations

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

NCT04269902629 locations

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

NCT047715728 locations